Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences IncfiledCriticalGilead Sciences Inc
Priority claimed from PCT/US2016/060989external-prioritypatent/WO2017083304A1/en
Publication of CU20180036A7publicationCriticalpatent/CU20180036A7/en
<p>Se proporciona una forma de dosificación oral sólida, que comprende un compuesto de Fórmula I o una sal farmacéuticamente aceptable del mismo, tenofovir alafenamida o una sal farmacéuticamente aceptable de Ia misma, y emtricitabina o una sal farmacéuticamente aceptable de Ia misma.</p><p> A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof. < / p>
CUP2018000036A2015-11-092016-11-08
THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
CU20180036A7
(en)